Scancell Holdings plc (LON:SCLP – Get Free Report) shares traded down 10.4% during trading on Wednesday . The company traded as low as GBX 23 and last traded at GBX 23.75. 3,199,308 shares changed hands during mid-day trading, an increase of 64% from the average session volume of 1,951,172 shares. The stock had previously closed at GBX 26.50.
Scancell Stock Down 13.0%
The stock has a market capitalization of £239.21 million, a price-to-earnings ratio of -41.91 and a beta of 0.57. The business has a fifty day moving average of GBX 14.07 and a 200 day moving average of GBX 12.26. The company has a debt-to-equity ratio of -193.29, a current ratio of 0.56 and a quick ratio of 13.01.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Featured Stories
- Five stocks we like better than Scancell
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
